Results : We detected anti-nAQP4-IgG with a sensitivity of 57.9% and specificity of 100% in patients with NMO spectrum diseases, suggesting that our bioassay is at least as sensitive and specific as the gold-standard NMO-IgG assay. The anti-AQP4 antibodies belonged predominantly to the IgG1 isotype and bound with high affinity to the extracellular domain of nAQP4. Our data suggest that the autoantibody exerts pathological properties because nAQP4-IgGpositive sera induced cell death of nAQP4-expressing cells by antibody-dependent cellular natural killer cell cytotoxic effect and complement activation. Furthermore, nAQP4-IgG titers strongly correlated with in vitro cytotoxic effect.
Conclusions:
In NMO, this assay may help to unravel the biological function of anti-nAQP4-IgG. Our findings demonstrate the potential of bioassays to characterize biologically relevant antibodies in human autoimmune diseases.
Arch Neurol. 2010;67 (10):1201-1208 N EUROMYELITIS OPTICA (NMO) is an autoimmune disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. 1, 2 The spectrum of NMO-related diseases also includes relapsing inflammatory optic neuritis (RION) and longitudinally extensive transverse myelitis (LETM). In most patients a specific serum autoantibody is found (NMO-IgG), which targets aquaporin 4 (AQP4), a water channel predominantly expressed on astrocytes in the spinal cord, optic nerve, and periventricular hypothalamic area. 3, 4 Several clinicopathological correlations have implicated NMO-IgG in NMO pathogenesis. First, a marked loss of AQP4 is observed in CNS lesions of NMO-IgGpositive patients. 5 Second, the anti-AQP4 antibody titers correlate with the extent of spinal lesions at the nadir of NMO exacerbations. 6 Third, serum anti-AQP4 antibody titers correlate with clinical disease activity. 7 Recently, anti-AQP4
antibodies were shown to activate complement, 8, 9 induce degranulation of natural killer (NK) cells, 10 disrupt glutamate homeostasis, 11 and reproduce NMO pathology in inflammatory autoimmune models in vivo. 12, 13 It still remains elusive, however, why other organs with high AQP4 expression such as the kidneys are not affected by the autoimmune process.
Different assays have been established to measure antibodies targeting AQP4 in NMO spectrum disease. While indirect immunofluorescence (IF) using mouse brain sections remains the gold standard for the detection of NMO-IgG, 4 new quantitative IF, immunoprecipitation (IP), 3, 4, 8, 14, 15 and radioimmunoprecipitation 16 assays have been developed. Nevertheless, a significant proportion (about 40%-50%) of sera from patients with clinically definite NMO are negative for anti-AQP4 antibodies in the available assays. One possible explanation might be that none of the assays fully reflect the posttranslational modification of AQP4 that occurs in human glial cells, leading to a false-negative result. Given the potential functional importance of antibodies targeting conformational epitopes of membrane proteins in other CNS diseases and experimental models, [17] [18] [19] [20] assays that precisely reflect expression of the protein in vivo are desperately needed.
Therefore, we established a bioassay that allows quantification of antibodies to human native AQP4 (nAQP4) expressed in a human astrocytoma cell line (nAQP4-IgG). The assay was validated with well-defined sets of sera and was used to investigate the biological activity of anti-nAQP4-IgG in vitro. Complement-and NK cellmediated cytotoxic effects were observed with all sera containing antibodies to nAQP4. The strong correlation between antibody titer and in vitro cytotoxic effect suggests that the bioassay reliably detects biologically relevant antibodies in NMO and NMO spectrum diseases. Cellbased assays are powerful tools to investigate antibody responses to membrane proteins and may help identify and characterize antibody responses relevant in other autoimmune diseases.
METHODS

PATIENTS AND CONTROLS
For initial validation of the assay, sera from 14 patients with NMO or opticospinal multiple sclerosis (MS) (13 women, 1 man) participating in clinical studies at the University of California, San Francisco were used. Patients with opticospinal MS were defined as those meeting International Panel Criteria for MS but having clinical attacks restricted to the optic nerves or spinal cord and disease duration of at least 5 years. All subjects provided written informed consent, and the studies received approval from the committee on human research.
For further evaluation of the assay, an independent cohort of 57 patients with NMO spectrum diseases was recruited from various neurology centers in Hungary. Sera and detailed clinical data were collected at the Department of Neurology, University of Pecs, Pecs, Hungary, and all patients were examined by neurologists specialized in neuroimmunology or MS care. Each patient has had brain and spinal cord magnetic resonance imaging (1.5 or 3 T). Based on clinical and paraclinical data, patients were diagnosed according to the revised criteria by Wingerchuk et al, 21 with the exception of NMOautoantibody status, which had not been determined beforehand. The cohort comprised 18 patients fulfilling the diagnostic criteria for NMO (15 
CLONING AND EXPRESSION OF AQP4
The human M1 and M23 variants of AQP4 were expressed by a lentiviral transfection system in the LN18 cell line as described previously. 17 The LN18 cell line is a human glioma cell line established from an astrocytoma biopsy specimen. 23 Total human brain RNA (BD Biosciences, San Jose, California) was used to synthesize full-length complementary DNAs of the M1 and M23 AQP4 variants (with SpeI and SacII restriction sites at 5Ј and 3Ј ends). The sequence of the common reverse primer used for both M1 and M23 variants was 5Ј-CCG CGG GTC TGC TTT CAG TGC GAT CTT CTA G-3Ј. Sequences of the forward primers were 5Ј-ACT AGT GCA ATG AGA GCT GCA CTC TGG CTG-3Ј for the M1 variant and 5Ј-ACT AGT ATG GTG GCT TTC AAA GGG GTC TGG-3Ј for the M23 variant. The polymerase chain reaction-amplified products were cloned into the plasmid pLenti6/V5 (Invitrogen Corp, Carlsbad, California) by using SpeI and SacII restriction sites. To generate genecontaining virus particles, the pLenti6/V5-AQP4 M1 or M23 constructs and packaging mix were used to transfect a 293 FT cell line by Lipofectamine 2000 (Invitrogen Corp). After transfection of 48 hours, virus-containing supernatant was collected and used to transduce the human LN18 astrocytoma cell line to generate both M1-and M23-expressing cell lines (LN18 AQP4 and LN18 AQP4-M23 , respectively). The LN18 cell line was also transduced with an empty vector pLenti6/V5 to establish a control cell line (LN18 CTR ). The 3 stably transduced cell lines were maintained under the same culture conditions and the same selection pressure throughout the experiments.
INDIRECT IF STAINING
The LN18 AQP4 and LN18 CTR cells were fixed for 10 minutes on ice with cytofix (BD Biosciences). After fixation, cells were blocked for 1 hour with blocking buffer containing 10% normal goat serum (Vector Laboratories, Inc, Burlingame, California). Extensive washing was performed at each step with washing buffer (0.05% Tween 20 [Sigma-Aldrich Co, St Louis, Missouri] in 1ϫ phosphate-buffered saline [PBS]). After blocking, cells were incubated with polyclonal rabbit antirat AQP4 IgG antibody (Sigma-Aldrich Co), which cross-reacts with human AQP4. The antibody targets amino acids 249 to 323 of the intracellular domain of the rat protein, which is 95% similar to the human sequence. Cells were incubated with 200 µL of the antibody at a concentration of 1 µg/mL or with nAQP4-IgG-positive serum (diluted 1:1000 in blocking buffer). Cells were incubated for 2 hours on ice, washed 5 times with washing buffer, and incubated for 1 hour with Alexa Fluor-488-labeled goat antirabbit IgG or goat antihuman IgG (Molecular Probes; Invitrogen Corp). The nuclei of the cells were counterstained with 4Ј,6-diamidino-2-phenylindole (Invitrogen Corp). Cells were mounted on slides in mounting medium (Vector Laboratories, Inc). Images were captured and analyzed with a fluorescence microscope (Fluorescence Microscope System, Carl Zeiss AG, Jena, Germany; or cell^R Imaging Station, Olympus, Essex, England).
WESTERN BLOT ANALYSIS
The LN18 AQP4 and LN18 CTR cells were lysed with RIPA buffer (Sigma-Aldrich Co). Five micrograms of total protein lysates of LN18 AQP4 and LN18 CTR was separated by using 10% Bis-Tris gels (Invitrogen Corp), and proteins were transferred to polyvinylidene fluoride membranes (Invitrogen Corp). The polyvinylidene fluoride membranes were blocked in blocking buffer (1ϫ PBS containing 4% milk and 0.05% Tween 20) for 1 hour at room temperature. The membranes were probed with rabbit polyclonal anti-AQP4-IgG antibody (stock [1 mg/mL]) diluted in blocking buffer (diluted 1:2000). Membranes were incubated overnight at 4°C, washed 5 times with washing buffer (0.05% Tween 20 in 1ϫ PBS), and incubated for 1 hour at room temperature with a horseradish peroxidase-conjugated goat antirabbit IgG (Fc) antibody (AbD Serotec, Raleigh, North Carolina) (1 mg/mL) diluted in blocking buffer (diluted 1:2000). Afterward, membranes were washed 5 times with washing buffer. Finally, antibody binding was detected by an Amersham ECL system (GE Healthcare, Piscataway, New Jersey) according to the manufacturer's instructions.
FLOW CYTOMETRY ANALYSIS
Flow cytometry was used first to confirm the expression of AQP4 in the LN18 AQP4 cell lines and second to identify anti-AQP4 autoantibodies in patients' sera.
The expression of AQP4 in LN18 AQP4 cells was determined by intracellular staining (for intracellular staining, cells were fixed and permeabilized with Cytofix and Cytoperm 
ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY ASSAY
We isolated CD56 ϩ NK cells from peripheral blood mononuclear cells of healthy donors separated by density gradient centrifugation (Biocoll Separating Solution; Biochrom, Cambridge, England). We incubated 1ϫ10 7 peripheral blood mononuclear cells with 20 µL of CD56 MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany) and 80 µL of MACS buffer (2.5 g of bovine serum albumin and 2 mL of 0.05M EDTA in 500 mL of 1ϫ PBS) on ice on an orbital shaker for 15 minutes. After incubation, the cells were washed with and resuspended in 2 mL of MACS buffer. The CD56 ϩ cells were then separated using magnetic cell separation (AutoMACS; Miltenyi Biotec). Purity of more than 95% NK cells was obtained.
Total IgG was purified from nAQP4-IgG-positive and nAQP4-IgG-negative sera by using Sepharose-G according to the manufacturer's protocol (GE Healthcare). We added 10 µg of purified IgG diluted in 40 µL of RPMI growth medium in duplicate to a U-shaped 96-well plate (CellStar; Greiner BioOne, Monroe, North Carolina), each well containing 30 000 LN18 CTR or LN18 AQP4 cells in 40 µL of RPMI medium (final IgG concentration was 125 µg/mL) and incubated on ice for 25 minutes on an orbital shaker. Cells were then washed twice with FACS buffer (1% fetal calf serum in 1ϫ PBS), washed once with RPMI medium, and transferred to a 96-well cell culture plate (F-bottom, CellStar). We added 60 000 CD56 ϩ NK cells resuspended in 40 µL of RPMI medium to each well, and RPMI medium was adjusted to a final volume of 150 µL. After incubation at 37°C in a humidified carbon dioxide incubator for 12 hours, the supernatants were discarded. Remaining cells were detached by 70 µL of 0.05% trypsin-EDTA and transferred into FACS tubes (BD Biosciences). Cell number and viability were determined by flow cytometry (CyAn ADP) based on forward scatter and sideward scatter parameters.
COMPLEMENT-MEDIATED CYTOTOXICITY ASSAY
On a U-shaped 96-well plate (CellStar), each well was loaded with 50 000 LN18 CTR or LN18 AQP4 cells in 40 µL of RPMI medium. Total IgG from nAQP4-IgG-positive and nAQP4-IgGnegative sera was purified as described earlier, diluted in 40 µL of RPMI growth medium, and added to each well to give a final IgG concentration of 125 µg/mL, in duplicate. Cells were incubated on ice for 25 minutes on an orbital shaker, washed twice with FACS buffer (1% fetal calf serum in 1ϫ PBS) and once with RPMI medium, and transferred to a 96-well cell culture plate (F-bottom, CellStar). A total of 7.5 µL of nAQP4-IgG-negative serum was added as a complement source in each well, and RPMI medium was adjusted to a final volume of 150 µL (final dilution of control serum was 1:20). After incubation at 37°C in a humidified carbon dioxide incubator for 12 hours, the supernatants were discarded and the remaining cells were detached by adding 70 µL of 0.05% trypsin-EDTA and transferred into FACS tubes. Cell number and viability were measured by flow cytometry (CyAn ADP) based on forward scatter and sideward scatter parameters.
RESULTS
RECOMBINANT EXPRESSION OF nAQP4 IN A HUMAN ASTROCYTOMA CELL LINE
To investigate antibody reactivity to nAQP4, we expressed the human M1 AQP4 gene in the human astrocytoma cell line LN18 (LN18 AQP4 ) by a lentiviral expression system (expression and detection strategy displayed in Figure 1A) . In parallel, the LN18 cell line was transduced with an empty vector to establish an appropriate control cell line (LN18 CTR ). Expression of AQP4 in LN18 AQP4 but not LN18 CTR was demonstrated by Western blot ( Figure 1B , data not shown).
QUANTIFICATION OF SERUM ANTIBODIES TO nAQP4 BY A CELL-BASED BIOASSAY
Serum antibodies from healthy control donors did not bind to either of the 2 cell lines ( Figure 2B , upper panel). Serial dilution of sera from NMO-IgG-positive patients demonstrated that the antibody to nAQP4 can be detected at a dilution of up to 1:100 000 ( Figure 2C and D). After logarithmic transformation, dose-response curves were approximately linear ( Figure 2D ). This indicates that the bioassay is able to detect nAQP4-IgG autoantibodies in serum samples in a quantitative manner over a wide range of concentrations.
COMPARATIVE ANALYSIS OF NMO-IgG AND ANTI-nAQP4-IgG
Next, we wished to validate our assay in comparison with an already established assay for the detection of NMO-IgG. Thus, our assay was applied to 14 serum (Table) . Eight samples tested positive by IF and IP, 1 sample tested positive by IP but not IF, and 5 samples were negative in both assays. In our assay, all 9 NMO-IgGpositive samples were strongly positive, although titers differed by more than 1 order of magnitude. Interestingly, the difference in the MFI (⌬MFI) of the IP-positive/IF-negative serum was in the midrange. Further, 4 of 5 NMO-IgG-negative sera were below the cutoff of our assay as well, but 1 NMO-IgG-negative serum tested strongly positive. Although these data are derived from a rather small sample set and are thus preliminary, the results suggest that our cell-based assay is comparable to the current gold-standard NMO-IgG assays in terms of sensitivity and specificity. Similar results were obtained with the LN18 cell line transfected with the M23 variant of AQP4 (LN18 ), although serum antibody binding seemed to be slightly lower with this cell line compared with the LN18 AQP4 cell line (data not shown).Therefore, all further analyses were performed with the LN18 AQP4 cell line.
PREVALENCE OF ANTI-nAQP4-IgG IN NMO SPECTRUM DISEASES
To determine the sensitivity and specificity of our assay, we applied the assay to masked serum samples from patients with NMO, LETM, RION, MS, and OND ( Figure 3A ). Sera were diluted 1:100 and tested in duplicates using ⌬MFI as compared with background staining as the readout.
To define a cutoff for anti-nAQP4-IgG antibody positivity, sera from 64 patients with ONDs were measured as negative controls. The ⌬MFI ranged from −8.1 to 5.0, with a median of −0.63. The cutoff was thus set at a ⌬MFI of 10, corresponding to twice the 99th percentile of the OND control group.
No sera from patients with MS tested positive for antinAQP4-IgG (median ⌬MFI, −0.81; range, −8.3 to 5.1). In contrast, anti-nAQP4-IgG antibodies were present in 11 of 18 patients with clinical NMO (61.1%; median ⌬MFI, 186; range, −3.5 to 1638.5), 5 of 12 patients with RION (41.7%; median ⌬MFI, 1.8; range, −3.3 to 1414.0), and 10 of 27 patients with LETM (37.0%; median ⌬MFI, 3.6; range, −6.7 to 1413.8). In 22 of 27 anti-nAQP4-IgGpositive patients, serum concentrations were considered high because they exceeded a ⌬MFI of 100 ( Figure 3A) . Low titers were observed in 4 patients with LETM and 1 patient with NMO. The specificity and positive predictive value of our assay were 100%. The sensitivity was 57.9% with respect to NMO spectrum diseases; the negative predictive value was 66.6%. In line with previous findings, 4,7 the highest number of patients with anti-nAQP4 antibodies and the highest titers were observed in the NMO group.
ISOTYPE OF ANTI-nAQP4-IgG
To determine the isotype of the anti-nAQP4-IgG, we analyzed all positive serum samples using secondary antibodies specific for human IgG1, IgG2, IgG3, and IgG4. Significant levels of nAQP4-specific antibodies were found only when the secondary antibody targeted IgG1 ( Figure 3B ). In line with this finding, a strong correlation between the levels of anti-nAQP4-IgG and anti-nAQP4-IgG1 was observed ( Figure 3C ). IgM antibodies to nAQP4 were not found in any of the anti-nAPQ4-IgG-positive patients at a serum dilution of 1:100.
DETECTION OF ANTI-nAQP4-IgG IN CEREBROSPINAL FLUID
To address the question of intrathecal production of antinAQP4-IgG antibodies, we determined the antibody index (AI). The AI is described by the formula AI=Q spec / Q IgG , with Q representing the cerebrospinal fluid (CSF)/ serum quotient of nAQP4-IgG antibodies (Q spec ) or total IgG (Q IgG ). An AI greater than 1.5 indicates a production of antibodies in the CNS compartment by sequestered plasma cells or plasma blasts (intrathecal synthesis of the specific antibody). 24 Corresponding CSF samples from anti-nAQP4-IgG-positive sera were available from 7 patients with NMO spectrum diseases in whom CSF and serum samples had been collected at the same time. After adjusting for total IgG concentration (Q IgG =1), pairs of serum and CSF samples were subjected to the nAQP4 assay in parallel. In 3 of 7 paired samples, the AI was between 1.0 and 1.5; in the remaining 4 paired samples, the AI was below 1.0 ( Figure 3D ). Thus, we have no evidence of intrathecal nAQP4-IgG synthesis in this preliminary analysis. 
BIOLOGICAL ACTIVITY OF ANTI-nAQP4-IgG
To investigate whether nAQP4-IgG is biologically active, we tested the serum IgG antibodies for their ability to induce a cytotoxic effect in LN18 AQP4 glioma cells in the presence of complement or human NK cells (Figure 4) . In the presence of NK cells, IgG from antinAQP4-IgG-positive sera induced a specific, dosedependent cytotoxic effect in LN18 AQP4 cells but not LN18 CTR cells (Figure 4A and B) . This effect was evident even at an IgG concentration of 1.25 µg/mL ( Figure 4A ). The extent of NK cell-mediated cytotoxic effect strongly correlated with the serum concentration of anti-nAQP4-IgG (r =0.8763; P =.01) ( Figure 4C ). We also observed a complement-mediated cytotoxic effect in LN18 AQP4 cells incubated with IgG purified from anti-nAQP4-IgGpositive sera ( Figure 4D ). The extent of killing was less pronounced compared with the NK cell-mediated killing but again correlated well with the serum levels of antinAQP4-IgG (r=0.9515; P=.001).
COMMENT
We present data of our novel bioassay for the detection of nAQP4-IgG. The advantage of our assay is 2-fold. First, the The LN18  AQP4 and  LN18 CTR cells were incubated with 125-µg/mL total IgG purified from nAQP4-IgG-positive sera of patients with NMO or nAQP4-IgG-negative sera of patients. Survival of LN18 cells in the presence of anti-nAQP4-IgG-negative serum as a complement source was determined after 12 hours and normalized to the negative control sample (LN18 cells alone).
(REPRINTED) ARCH NEUROL / VOL 67 (NO. 10), OCT 2010 WWW.ARCHNEUROL.COMtarget antigen is expressed in a human cell line of glial origin and displayed on the membrane of the cells, similar to the expression in human astrocytes. Second, only those antibody reactivities that are directed against extracellular epitopes are measured. We demonstrate that these antibodies confer biological activity and may thus be pathogenetically relevant because we provide evidence for anti-AQP4-IgG antibody-mediated cytotoxic effect. Aquaporin 4 is hypothesized to be the major autoimmune target in NMO spectrum diseases. 4 It is a membrane protein with several transmembrane domains that exists in at least 2 isoforms. 25, 26 It is expressed in astrocytes but also in the distal collecting ducts of the kidney and parietal cells of the stomach. 27 Antibodies to AQP4 are found in a significant proportion of patients with NMO, RION, and LETM but not in those with MS or other autoimmune diseases of the CNS. 4, 5, [14] [15] [16] 27 Interestingly, autoimmunity seems to exclusively target AQP4 in the CNS as neither renal nor parietal cell dysfunction has been described in patients with NMO. This may suggest that the AQP4 protein expressed in the brain differs from the protein expressed outside the CNS. It is well known that tissuespecific posttranslational modifications that alter protein structure and function may occur. In the case of NMO spectrum diseases, expression of AQP4 in astrocytes may render the protein particularly immunogenic. Alternatively, astrocytes might be more vulnerable to anti-AQP4 antibody-mediated cytotoxic effect. Both conditions may account for the CNS-confined autoimmune reaction observed in NMO spectrum diseases.
To reflect the posttranslational modifications that might occur in astrocytes, we established a novel bioassay using a human AQP4-transfected cell line of glial origin. The glial cell line allowed us to express AQP4 protein at high levels on the surface of the cells, possibly with the posttranslational modifications occurring in astrocytes. This bioassay is at least as sensitive as the gold-standard assay, which was used to identify NMO-IgG. 3, 28 Its sensitivity and specificity also seem comparable to or even better than those of other assays that are based on transient transfection of AQP4 in cells of nonglial origin. 6, 29, 30 Moreover, the flow-based assay allows high-throughput analysis and quantification of antibody titers to AQP4, which simplifies testing for this autoantibody.
The new assay allowed characterization of the isotype and biological activity of antibodies that target AQP4. We confirmed the high prevalence of anti-nAQP4-IgG autoantibodies in a cohort of patients with NMO spectrum disease who had been selected solely on the basis of clinical criteria. The antibody response to nAQP4 was almost exclusively IgG1. We found little evidence for a quantitative production of AQP4-specific antibodies in the CSF compartment, although locally produced antibodies may rapidly bind AQP4 in the CNS and thus escape detection by the assay. The AQP4-positive sera very efficiently induced complement-and NK celldependent cytotoxic effects of AQP4-expressing glioma cells. Interestingly, nAQP4-IgG concentrations correlated strongly with the extent of cytotoxic effect, suggesting that the antibodies detected with our assay represent the biologically active fraction of antibodies targeting AQP4 in vivo. It is possible that the serum antinAQP4-IgG concentration might be useful to monitor disease activity in NMO spectrum diseases. 7, 9 It is yet unclear why one-third of patients with NMO spectrum disease are AQP4 antibody negative in our assay. It is still possible that AQP4 may undergo posttranslational modifications and clustering, which are not achieved even in a transfected tumor cell line derived from astrocytes. Alternatively, these AQP4 antibody-negative patients with NMO may have another yet unknown autoantigen targeted in the CNS.
Besides the implications for the understanding of NMO spectrum diseases, our findings underscore the need for improved assay systems for detection of autoantibodies that target membrane proteins in human autoimmune diseases. The importance of antibodies targeting native vs denatured proteins was demonstrated in experimental autoimmune encephalomyelitis models induced by human myelin oligodendrocyte glycoprotein. While antibodies reactive to both denatured and native myelin oligodendrocyte glycoprotein are found in myelin oligodendrocyte glycoprotein-immunized animals, only antibodies targeting native myelin oligodendrocyte glycoprotein can mediate demyelination in vivo. 31 Therefore, expression systems displaying the protein in the proper conformation are desperately needed to identify antibodies of relevance for human autoimmune diseases. Such bioassays not only allow more accurate antibody measurement but also enable determination of their biological activity with respect to various mechanisms of antibody-mediated cytotoxic effect. The implementation of such bioassays for the search for autoantibodies in human autoimmune diseases might allow us to discover and characterize antibodies that have escaped identification by screening with conventional assays.
